The Administrative Core provides the infrastructure for and coordinates all activities of the MPD Research Consortium (MPD-RC). Key functions include organizational management and communication, resource allocation and management (personnel, funds,equlpment, and supplies), organization of all internal and external advisory boards, scientific and clinical trials oversight to assure regulatory cornpliarice and procedural implementation, and exetmal liaison to appropriate governmental agencies.
The specific aims of the Administrative are: 1) coordinate activities of all projects, and cores belonging to the MPD-RC;2) schedule and provide optimal staff support for all MPD-RC committees and boards and establish and staff new committees when necessary;3) assure that the use of both human subjects and animal subjects is monitored in compliance with NIH regulations for research using human subjects and animals;4) administer and oversee all budgets;5) liaison to the NCI for all matters pertaining to the MPD-RC;6) submit all applications for use of Investigational New Drugs (IND) to the U.S. Federal Drug Administration;7) report all adverse events experienced by patients participating in clinical trials to investigators, participating instituions and appropriate regulatory agencies;8) develop and negotiate contracts with pharmaceutical companies to gain access to drugs to be administered in clinical trials and obtain partial support from pharmaceutical companies for the performance of these trials;9) prepare and provide yearly progress reports to the NCI.

Public Health Relevance

The Administrative Core is a critical resource which coordinates the activities of the 6 projects and other cores which comprise the MPD-RC. This core provides an organizational foundation which permits the investigators who are located at multiple geographic sites across 9 time zones to closely and effectively interact.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA108671-08
Application #
8722852
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
8
Fiscal Year
2014
Total Cost
$379,235
Indirect Cost
$209,635
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388
Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787
Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:
Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13
Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :
Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587
Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179
Ling, Te; Crispino, John D; Zingariello, Maria et al. (2018) GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. Expert Rev Hematol 11:169-184

Showing the most recent 10 out of 195 publications